Abstract
Keywords
Cytotoxic activity Benzoxazin Quinazolin Antitumor Docking analysis
Introduction
The synthesis of quinazolinone heterocycles has become the cornerstone for synthetic chemists and gained extensive importance in medicinal chemistry because of their diverse pharmacological activities including anti-mycobacterial (1-3), anti-fungal (4), antimalarial (5), antihypertensive (6-8), anti-histaminic (9-13), cardiotonic (14), anticancer (15-17), antiviral (18) and thymidylate synthase inhibitory activities (19, 20).
Substituted quinazolin-3(4H)-ones are among the versatile heterocyclic compounds, as they have a broad spectrum of pharmacological activities like anti-inflammatory (21), anticonvulsant (22-24), analgesic (25), antitubercular (26, 27) and anticancer activities (28-32).
Benzoxazine heterocyclic compounds are potent non-steroidal progesterone receptor agonists (33) having many other activities such as anticancer, antiangiogenic (34), antidiabetic and hypolipidemic (35), antidepressant (36) and antiplatelet aggregation activities (37).
Epidermal growth factor receptor (EGFR), which is cellular trans-membrane tyrosine kinase, is over-expressed in a significant number of human tumors (e.g., breast, ovarian, colon, and prostate). An EGFR expression level often correlates with vascularity, and is associated with poor prognosis in patients. Inhibitors of the EGFR protein tyrosine kinase are, therefore, expected to have great therapeutic potential in the treatment of malignant and nonmalignant epithelial diseases (38-43). These findings encourage us to synthesize novel 3, 1-benzoxazin-4-one derivatives.
Experimental
Chemistry
All melting points are uncorrected and were taken on electro-thermal capillary melting point apparatus. Infrared spectra were recorded on a Jasco FT/IR-6100, Fourier transforms, Infrared spectrometer (Japan) at cm-1 scale using the KBr disc technique in the Central Services Laboratory, National Research Center, Dokki, Cairo, Egypt. 1H NMR spectra were determined by using a JEOl EX-270 NMR spectrometer (Japan) at the Central Services Laboratory, National Research Center, Dokki, Cairo, Egypt. The mass spectra were measured with a Finnigan MAT SSQ-7000 mass spectrometer at the Central Services Laboratory, Cairo University, Giza, Egypt. Follow up of the reactions and checking the purity of the compounds were made by TLC on silica gel-precoated aluminum sheets (Type 60, F 254, Merck, Darmstadt, Germany) and the spots were detected by exposure to UV analysis lamp at λ 254/366 nm for few seconds.
General procedure for the preparation of compounds (3a, c, d)
A solution of acid chloride (2a, c, d) (0.01 mol) and anthranilic acid (0.01 mol) in dry pyridine (30 mL) was refluxed for 3 h, the reaction mixture was cooled and poured into cold diluted HCl. The precipitate was collected by filtration and recrystallized from a proper solvent to give (3a, c, d). Spectroscopic data for all the compounds are given below.
2-(Pyridin-3-yl)-4H-3, 1-benzoxazin-4-one (3a)
Yield 80%. Yellow, white crystals. mp. 210-217 ˚C, IR (KBr, cm-1): 1700 (C = O). 1H NMR (DMSO-d6, δ ppm): 7.50-9.03 (m, 8H, aromatic). MS: (m/z) ≈ 224 (10%). Anal. Calcd for C13H8N2O2 (224.21): C, 69.64; H, 3.60; N, 12.49%. Found: C, 69.43; H, 3.44; N, 12.14%.
2-(Pyridin-4-yl)-4H-3, 1-benzoxazin-4-one (3c)
Yield 85%. Yellow crystals. mp >300 ˚C, IR (KBr, cm-1): 1692 (C = O). 1H NMR (DMSO-d6, δ ppm): 7.42-9.21 (m, 8H, aromatic). MS: (m/z) ≈ 224 (15%). Anal. Calcd for C13H8N2O2 (224.21): C, 69.64; H, 3.60; N, 12.49%. Found: C, 69.55; H, 3.51; N, 12.25%.
2-[2-(Phenylamino) phenyl]-4H-3, 1-benzoxazin-4-one (3d)
Yield 85%. Yellow crystals. mp. 235-240 ˚C, IR (KBr, cm-1): 1690 (C = O) and 3170 (NH). 1H NMR (DMSO-d6, δ ppm): 7.20-8.20 (m, 13H, aromatic), 11.72 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 314 (5%). Anal. Calcd for C20H14N2O2 (314.33): C, 76.42; H, 4.49; N, 8.91%. Found: C, 76.03; H, 4.20; N, 8.34%.
General procedure for the preparation of compounds (4a, b)
A mixture of (3a (44), 3b (45)) (0.01 mol) and formamide (0.015 mol) was refluxed for 3 h in boiling ethanol (30 mL), then poured into water. The precipitated solid after concentration and cooling was collected by filtration and crystallized from the proper solvent to give (4a, b). Spectroscopic data for all the compounds are given below.
2-(Pyridin-3-yl) quinazolin-4 (3H)-one (4a):
Yield 65%, White crystals. mp. >300 ˚C, IR (KBr, cm-1): 1700 (C = O) and 3299 (NH). 1H NMR (DMSO-d6, δ ppm): 7.23-8.32 (m, 8H, aromatic), 12 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 223 (0.13%). Anal. Calcd for C13H9N3O (223.23): C, 69.95; H, 4.06; N, 18.82%. Found: C, 69.62; H, 3.88; N, 18.60%.
2-[(E)-2-(furan-2-yl) ethenyl] quinazolin-4 (3H)-one (4b)
Yield 85%. Black crystals. mp. 170-175 ˚C, IR (KBr, cm-1): 1698 (C = O) and 3150 (NH). 1H NMR (DMSO-d6, δ ppm): 6.48 (d, J = 5.4 Hz, 1H, CH), 6.89 (d, J = 2.7 Hz, 1H, CH), 7.11-8.59 (m, 7H, aromatic), 11.78 (s, 1H, NH, exchangeable with D2O).MS: (m/z) ≈ 238 (10%). Anal. Calcd for C14H10N2O2 (238.24): C, 70.58; H, 4.23; N, 11.76%. Found: C, 70.30; H, 4.08; N, 11.50%.
General procedure for the preparation of compounds (5a, b)
A mixture of (4a, b) (0.01 mol) and chloroacetyl chloride (0.01 mol) was refluxed in boiling N, N-dimethylformamide (DMF) (30 mL) for 3 h. Then the mixture was poured into water. The precipitate was collected by filtration, dried and crystallized from the proper solvent to give (5a, b). Spectroscopic data for all the compounds are given below.
3-(Chloroacetyl)-2-(pyridin-3-yl) quinazolin-4 (3H)-one (5a)
Yield 80%. Gray crystals. mp. >300 ˚C, IR (KBr, cm-1): 1650 (C = O) and 1690 (C = O). 1H NMR (DMSO-d6, δ ppm): 4.48 (s, 2H, CH2), 7.63-9.07 (m, 8H, aromatic). MS: (m/z) ≈ 299 (6%), [M + 2]+ m/z ≈ 301 (3%). Anal. Calcd for C15H10ClN3O2 (299.71): C, 60.11; H, 3.36; N, 14.02%. Found: C, 59.90; H, 2.98; N, 13.90%.
3-(Chloroacetyl)-2-[(E)-2-(furan-2-yl) ethenyl] quinazolin-4 (3H)-one (5b)
Yield 90%. Black crystals. mp. 151-155 ˚C, IR (KBr, cm-1): 1690 (C = O) and 1710 (C = O). 1H NMR (DMSO-d6, δ ppm): 4.90 (s, 2H, CH2), 6.23 (d, J = 8.1 Hz, 1H, CH), 6.70 (d, J = 5.4 Hz, 1H, CH), 6.95-8.21 (m, 7H, aromatic). MS: (m/z) ≈ 314 (1.8%), [M+2] + m/z ≈ 316 (1%). Anal. Calcd for C16H11ClN2O3 (314.72): C, 61.06; H, 3.52; N, 8.90%. Found: C, 60.90; H, 3.30; N, 8.67%.
General procedure for the preparation of compounds (6a, b)
A mixture of (5a, b) (0.01 mol) and hydrazine hydrate (0.015 mol) was heated in boiling ethanol (30 mL) under reflux for 4 h. Then the mixture was poured into water. The precipitate was collected by filtration, dried and crystallized from the proper solvent to give (6a, b). Spectroscopic data for all the compounds are given below.
3-(Hydrazinylacetyl)-2-(pyridin-3-yl) quinazolin-4 (3H)-one (6a)
Yield 75%. Gray crystals. mp. 106-110 ˚C, IR (KBr, cm-1): 1690, 1700 (2C = O), 3190 (NH) and 3300-3444 (NH2). 1H NMR (DMSO-d6, δ ppm): 3.55 (s, 2H, CH2), 3.80 (s, 2H, NH2, exchangeable with D2O), 7.58-9.07 (m, 8H, aromatic), 10.49 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 295 (12%). Anal. Calcd for C15H13N5O2 (295.29): C, 61.01; H, 4.44; N, 23.72%. Found: C, 60.85; H, 4.20; N, 23.50%.
2-[(E)-2-(furan-2-yl) ethenyl]-3-(hydrazinylacetyl) quinazolin-4 (3H)-one (6b)
Yield 65%. White crystals. mp. > 300 ˚C, IR (KBr, cm-1): 1687, 1697 (2C = O), 3174 (NH) and 3320-3400 (NH2). 1H NMR (DMSO-d6, δ ppm): 3.49 (s, 2H, CH2), 3.70 (s, 2H, NH2, exchangeable with D2O), 6.65, 6.90 (2d, J = 5.4 Hz, J = 2.7 Hz, 2H, 2CH), 7.01-8.48 (m, 7H, aromatic), 11.21 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 310 (3%). Anal. Calcd for C16H14N4O3 (310.30): C, 61.93; H, 4.55; N, 18.06%. Found: C, 61.70; H, 4.35; N, 17.80%.
General procedure for the preparation of compounds (7c, d)
A solution of (3c, d) (44) (0.01 mol) in dry benzene (30 mL) and hydrazine hydrate (0.015 mol) was heated under reflux for 4 h. Then the mixture was poured into water. The precipitate was collected by filtration, dried and crystallized from the proper solvent to give (7c, d) (44). Spectroscopic data for all the compounds are given below.
3-Amino-2-(pyridin-4-yl) quinazolin-4 (3H)-one (7c)
Yield 75%, Black crystals. mp. 150-155 ˚C, IR (KBr, cm-1): 1685 (C = O) and 3311-3420 (NH2). 1H NMR (DMSO-d6, δ ppm): 7.68-8.66 (m, 8H, aromatic), 10.08 (s, 2H, NH2, exchangeable with D2O). MS: (m/z) ≈ 238 (15%). Anal. Calcd for C13H10N4O (238.24): C, 65.54; H, 4.23; N, 23.52%. Found: C, 65.32; H, 4.18; N, 23.40%.
3-Amino-2-[2-(phenylamino) phenyl] quinazolin-4 (3H)-one (7d)
Yield 85%. Yellow crystals. mp. 260-265 ˚C, IR (KBr, cm-1): 1700 (C = O), 3172 (NH) and 3300-3434 (NH2). 1H NMR (DMSO-d6, δ ppm): 3.60 (s, 2H, NH2, exchangeable with D2O), 6.68-8.54 (m, 13H, aromatic), 12.01 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 328 (20%). Anal. Calcd for C20H16N4O (328.36): C, 73.15; H, 4.91; N, 17.06%. Found: C, 73.01; H, 4.75; N, 16.90%.
General procedure for the preparation of compounds (8c, d)
A solution of (7c, d) (44) (0.01 mol), was allowed to react with chloroacetyl chloride (0.01 mol) in refluxing pyridine about 2 h, and then poured over ice/HCl. The precipitate was collected by filtration and crystallized from the proper solvent to give (8c, d). Spectroscopic data for all the compounds are given below.
2-Chloro-N-[4-oxo-2-(pyridin-4-yl) quinazolin-3 (4H)-yl] acetamide (8c)
Yield 70%. Yellow crystals. mp. > 300 ˚C, IR (KBr, cm-1): 1698, 1715 (2C = O) and 3175 (NH). 1H NMR (DMSO-d6, δ ppm): 4.78 (s, 2H, CH2), 7.65-8.44 (m, 8H, aromatic), 11.87 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 314 (8%), [M + 2] + m/z ≈ 316 (4%). Anal. Calcd for C15H11ClN4O2 (314.72): C, 57.24; H, 3.52; N, 17.80%. Found: C, 57.12; H, 3.40; N, 17.60%.
2-Chloro-N-{4-oxo-2-[2-(phenylamino) phenyl] quinazolin-3 (4H)-yl} acetamide (8d)
Yield 75%. Black crystals. mp. 190-195 ˚C, IR (KBr, cm-1): 1677, 1690 (2C = O) and 3230 (NH). 1H NMR (DMSO-d6, δ ppm): 4.90 (s, 2H, CH2), 6.81-8.20 (m, 13H, aromatic), 11.90, 12 (2s, 2H, 2NH, exchangeable with D2O). MS: (m/z) ≈ 404 (23%), [M + 2] + m/z ≈ 406 (15%). Anal. Calcd for C22H17ClN4O2 (404.84): C, 65.27; H, 4.23; N, 13.84%. Found: C, 65.05; H, 4.18; N, 13.75%.
General procedure for the preparation of compounds (9c, d)
A solution of compounds (7c, d) (44) (0.01 mol) and chloroacetamide (0.015 mol) was refluxed for 3 h in boiling N, N-dimethylformamide (DMF) (30 mL). Then the mixture was poured into water. The precipitate was collected by filtration, dried and crystallized from the proper solvent to give (9c, d). Spectroscopic data for all the compounds are given below.
6-(Pyridin-4-yl)-3, 4-dihydro-2H-[1, 2, 4] triazino [2, 3-c] quinazolin-2-one (9c)
Yield 65%. Black crystals. mp. > 300 ˚C, IR (KBr, cm-1): 1710 (C = O) and 3189 (NH). 1H NMR (DMSO-d6, δ ppm): 3.76 (s, 2H, CH2), 7.33-8.66 (m, 8H, aromatic), 10.70 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 277 (13%). Anal. Calcd for C15H11N5O (277.28): C, 64.97; H, 4.00; N, 25.26%. Found: C, 64.70; H, 3.88; N, 25.07%.
6-[2-(Phenylamino) phenyl]-3, 4-dihydro-2H-[1, 2, 4] triazino [2, 3-c] quinazolin-2-one (9d)
Yield 85%. Yellow crystals. mp. 256-260 ˚C, IR (KBr, cm-1): 1677 (C = O) and 3150 (NH). 1H NMR (DMSO-d6, δ ppm): 3.65 (s, 2H, CH2), 6.87-7.96 (m, 13H, aromatic), 10.70, 11.30 (2s, 2H, 2NH, exchangeable with D2O). MS: (m/z) ≈ 367 (19%). Anal. Calcd for C22H17N5O (367.40): C, 71.92; H, 4.66; N, 19.06%. Found: C, 71.76; H, 4.49; N, 18.89%.
General procedure for the preparation of compounds (10c, d)
A solution of compounds (7c, d) (44) (0.01 mol) and phenyl isothiocyanate (0.01 mol) was refluxed in boiling benzene (30 mL) for 3 h, then concentrated and crystallized from the proper solvent to give (10c, d). Spectroscopic data for all the compounds are given below.
1-[4-Oxo-2-(pyridin-4-yl) quinazolin-3 (4H)-yl]-3-phenylthiourea (10c)
Yield 90%. White crystals. mp. 195-200 ˚C, IR (KBr, cm-1): 1685 (C = O) and 3190 (NH). 1H NMR (DMSO-d6, δ ppm): 7.33-8.96 (m, 13H, aromatic), 10.49, 11.01 (2s, 2H, 2NH, exchangeable with D2O). MS: (m/z) ≈ 373 (5%). Anal. Calcd for C20H15N5OS (373.43): C, 64.33; H, 4.05; N, 18.75%. Found: C, 64.12; H, 3.90; N, 18.50%.
1-(4-Oxo-2-(2-(phenylamino) phenyl) quinazolin-3 (4H)-yl)-3-phenylthiourea (10d)
Yield 80%. Yellow crystals. mp. 200-205 ˚C, IR (KBr, cm-1): 1700 (C = O) and 3200 (NH). 1H NMR (DMSO-d6, δ ppm): 7.09-8.24 (m, 18H, aromatic), 9.77, 9.86, 11.70 (3s, 3H, 3NH, exchangeable with D2O). MS: (m/z) ≈ 463 (3%). Anal. Calcd for C27H21N5OS (463.55): C, 69.96; H, 4.57; N, 15.11%. Found: C, 69.69; H, 4.48; N, 14.90%.
General procedure for the preparation of compounds (11c, d)
A solution of (7c, d) (44) (0.01 mol) and benzoyl chloride (0.01 mol) in dry acetone (30 mL) was refluxed for 3 h. Excess solvent was removed and The precipitated solid obtained was crystallized from suitable solvent to obtain (11c, d). Spectroscopic data for all the compounds are given below.
N-[4-oxo-2-(pyridin-4-yl) quinazolin-3 (4H)-yl] benzamide (11c)
Yield 70%. Yellow crystals. mp. 180-185 ˚C, IR (KBr, cm-1): 1677, 1690 (2C = O) and 3150 (NH). 1H NMR (DMSO-d6, δ ppm): 7.31-8.42 (m, 13H, aromatic), 12.01 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 342 (17%). Anal. Calcd for C20H14N4O2 (342.35): C, 70.17; H, 4.12; N, 16.37%. Found: C, 70.02; H, 3.90; N, 16.17%.
N-(4-oxo-2-(2-(phenylamino) phenyl) quinazolin-3 (4H)-yl) benzamide (11d)
Yield 80%. Yellow crystals. mp. > 300 ˚C, IR (KBr, cm-1): 1687, 1693 (2C = O) and 3177 (NH). 1H NMR (DMSO-d6, δ ppm): 7.16-8.45 (m, 18H, aromatic), 11.01, 12.01 (2s, 2H, 2NH, exchangeable with D2O). MS: (m/z) ≈ 432 (10%). Anal. Calcd for C27H20N4O2 (432.47): C, 74.98; H, 4.66; N, 12.95%. Found: C, 74.70; H, 4.50; N, 12.80%.
General procedure for the preparation of compounds (12c, d)
A solution of (11c, d) (0.01 mol) with ammonium acetate (0.01 mol) in acetic acid (30 mL) was heated under reflux for 3 h, then poured into water. The precipitated solid after concentration and cooling was collected by filtration and crystallized from suitable solvent to give (12c, d). Spectroscopic data for all the compounds are given below.
2-Phenyl-5-(pyridin-4-yl) [1, 2, 4] triazolo [1, 5-c] quinazoline (12c)
Yield 65%. Gray crystals. mp. 215-220 ˚C, 1H NMR (DMSO-d6, δ ppm): 7.41-8.75 (m, 13H, aromatic). MS: (m/z) ≈ 323 (33%). Anal. Calcd for C20H13N5 (323.35): C, 74.29; H, 4.05; N, 21.66%. Found: C, 74.11; H, 3.89; N, 21.56%.
N-phenyl-2-(2-phenyl-[1, 2, 4] triazolo [1, 5-c] quinazolin-5-yl) aniline (12d)
Yield 85%. Yellow crystals. mp. 240-245 ˚C, IR (KBr, cm-1): 3177 (NH). 1H NMR (DMSO-d6, δ ppm): 6.69-8.28 (m, 18H, aromatic), 13 (s, 1H, NH, exchangeable with D2O). MS: (m/z) ≈ 413 (11%). Anal. Calcd for C27H19N5 (413.47): C, 78.43; H, 4.63; N, 16.94%. Found: C, 78.22; H, 4.48; N, 16.80%.
Cytotoxic effect on human cell line (HePG2 – MCF 7 - A549)
Cell viability was assessed by the mitochondrial dependent reduction of yellow MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) to purple formazan (46).
Procedure: All the following procedures were done in a sterile area using a Laminar flow cabinet biosafety class II level (Baker, SG403INT, Sanford, ME, USA). Cells were suspended in RPMI 1640 medium for HePG2- MCF7 and DMEM for A549. The media are supplemented with 1% antibiotic-antimycotic mixture (10,000 U/mL Potassium Penicillin, 10,000 µg/mL Streptomycin Sulfate and 25 µg/mL Amphotericin B), 1% L-glutamine and 10% fetal bovine serum and kept at 37 ºC under 5% CO2.
Cells were batch cultured for 10 days, then seeded at concentration of 10x103 cells/well in fresh complete growth medium in 96-well Microtiter plastic plates at 37 ˚C for 24 h under 5% CO2 using a water jacketed Carbon dioxide incubator (Sheldon, TC2323, Cornelius, OR, USA). Media was aspirated, fresh medium (without serum) was added and cells were incubated either alone (negative control) or with different concentrations of sample to give a final concentration of (100-50-25-12.5-6.25-3.125-0.78 and 1.56 µg/mL). After 48 h of incubation, the medium was aspirated, 40 µL MTT salt (2.5 μg/mL) were added to each well and incubated for a further four hours at 37 ºC under 5% CO2. To stop the reaction and dissolving the formed crystals, 200 μL of 10% Sodium dodecyl sulphate (SDS) in deionized water was added to each well and incubated overnight at 37 ºC. A positive control which composed of 100 µg/mL was used as a known cytotoxic natural agent who gives 100% lethality under the same conditions (47, 48).
The absorbance was then measured using a microplate multi-well reader (Bio-Rad Laboratories Inc., model 3350, Hercules, California, USA) at 595 nm and a reference wavelength of 620 nm. A statistical significance was tested between samples and negative control (cells with vehicle) using independent t-test by SPSS 11 program. DMSO is the vehicle used for dissolution of plant extracts and its final concentration in the cells was less than 0.2%. The percentage of change in viability was calculated according to the formula:
(Reading of extract/Reading of negative control)-1) x 100. A probit analysis was carried for IC50 and IC90 determination using SPSS 11 program.
Molecular docking study
All docking studies were performed using "Internal Coordinate Mechanics" (Molsoft ICM 3.5-0a).
Preparation of small molecule
Compounds 2d, 3a, 3b, 3d, 4a, 4b, 5a, 5b, 6a, 6b, 7c, 7d, 8d, 9c, 9d, 10c, 10d, 11c, 11d, 12c, 12d were built in Chem Draw Ultra version 11.0 and their energy minimized through Chem3D Ultra version 11.0/MM2, Jop Type: minimum RMS Gradient of 0.100, and saved as MDL Mol File (*.Mol).
Generation of Ligand and Enzyme Structures
The crystal structures of EGFR (PDB code: 1M17) complex were retrieved from the RCSB Protein Data Bank (http://www.rcsb.org/pdb/ home/home.do).
We inspect the quality of the PDB file that was used using the PROSESS (Protein Structure Evaluation Suite & Server) (http://www.prosess.ca/) (Figure 1, 2). In our investigation, the 3D-coordinates in X-ray crystal structure of EGFR in complex with the ligand, Erlotinib (PDB entry 1M17) was used as the receptor model in EGFR docking simulation (Figure 3). All bound waters ligands and cofactors were removed from the protein.
Docking using Molsoft ICM 3.5-0 a program
The conversion of our PDB file into an ICM object involves the addition of hydrogen bonds, assignment of atom types, and charges from the residue templates, then perform ICM small molecule docking through setup the receptor, review and adjust binding site makes receptor maps, then start docking simulation, followed by displaying the results. ICM stochastic global optimization algorithm attempts to find the global minimum of the energy function that include five grid potentials describing the interaction of the flexible ligand with the receptor and internal conformational energy of the ligand, during this process a stack of alternative low energy conformations is saved. All inhibitors were compared according to the best binding free energy (minimum) obtained among all the run.
Results and Discussion
Chemistry
Different acid chlorides namely, pyridine-3-carbonyl chloride, (2E)-3-(furan-2-yl) prop-2-enoyl chloride, pyridine-4-carbonyl chloride and 2-(phenylamino) benzoyl chloride 2a-d, respectively reacted with anthranilic acid to produce 2-[substituted]-4H-3, 1-benzoxazin-4-one 3a-d (Scheme 1). Compounds 3a, b reacted with formamide to give 2-(substituted) quinazolin-4 (3H)-one 4a, b which reacted with chloroacetyl chloride to give 3-(chloroacetyl)-2-[substituted] quinazolin-4 (3H)-one 5a, b (Scheme 1). Compounds 5a, b reacted with hydrazine hydrate to give 3-(hydrazinylacetyl)-2-[substituted] quinazolin-4 (3H)-one 6a, b (Scheme 1). The structures of all of the newly synthesized derivatives were established via the elemental analyses and IR, 1H NMR and mass spectral data. IR spectra of the compounds 6a, b exhibited characteristic absorption bands in the range 3174-3444 cm-1 due to the respective NH and NH2. 1H NMR (DMSO-d6) spectra of compounds 6a, b revealed signals at δ 3.70-3.80 ppm and 10.49-11.21 ppm representing NH2 and NH groups, respectively.
Also, compounds 3c, d reacted with hydrazine hydrate to give 3-amino-2-(substituted) quinazolin-4 (3H)-one 7c, d (Scheme 1) which reacted with chloroacetyl chloride to give 2-chloro-N-[4-oxo-2-(substituted) quinazolin-3 (4H)-yl] acetamide 8c, d (Scheme 2). IR spectra of the derivatives 8c, d exhibited the disappearance of the characteristic band of NH2 group and showed the presence of bands at the range 1690-1715 cm-1 corresponding to CO groups.
Finally, compounds 7c, d reacted with chloroacetamide, phenyl isothiocyanate and benzoyl chloride to give compounds 9-11 (c, d), respectively (Scheme 2). Compounds 11c, d reacted with ammonium acetate to give N-phenyl-2-(substituted-[1, 2, 4] triazolo [1, 5-c] quinazolin 12c, d (Scheme 2).
In-vitro Antitumor Screening against A549, HePG2 and MCF7 cell lines
The cytotoxic potencies of compounds 2d, 3a, 3b, 3d, 4a, 4b, 5a, 5b, 6a, 6b, 7c, 7d, 8d, 9c, 9d, 10c, 10d, 11c, 11d, 12c, 12d against a panel of three human tumor cell lines were investigated and compared with the reference drug doxorubicin (Table 1). The human tumor cell line panel consisted of breast carcinoma (MCF7), liver carcinoma (HePG2) and lung carcinoma (A549) using MTT assay. Tumor cells were incubated either alone (negative control) or with different concentrations of the test compounds (100–50–25–12.5–6.25–3.125–0.78 and 1.56 µM). With regard to sensitivity against individual cell lines, this class is more effective on hepatocellular carcinoma more than other two cell lines. Compound 10c showed selective potency against A549 cell line (IC50 = 72.2) as shown in Table 2. However, compounds 11d and 9d showed selective potency against HePG2 cell line with IC50 53.4 and 66.7 µg/ml, respectively, as shown in Table 3 and compounds 4b and 8d for MCF7 cell line with IC50 81.9 and 90.5 µg/mL, respectively as shown in Table 4. However, compounds 7d, 3d and 2d showed effectiveness against all cell lines with IC50 (62.6, 85.0 and 92.1 µg/mL), (65.1, 82.9 and 77.6 µg/mL) and (75.8, 81.9 and 86.1 µg/mL) for HePG2, MCF7 and A549 as shown in Table 3, 4, 2, respectively. In addition, compounds 10d and 6a displayed selective potency against A549 and HePG2 cell lines with IC50 of 88.4, 92.1 and 45.6, 32.8 µg/mL concentrations, respectively as shown in Table 2, 3. While compound 12d displayed selective potency against HePG2 and MCF7 cell lines with IC50 33.3 and 87.4 µg/mL, respectively. Moreover, Compounds 6a and 12d considered the most potent compounds against the HePG2 cell line, while compounds 7d, 3d, 9d, 10d, 11d and 2d possessed moderate antitumor activity compared to positive control doxorubicin.
Positive control Adrinamycin (Doxorubicin) [Mw = 579.99].
| IC50 (µg/mL) | |
|---|---|
| HEPG2 | 21.6 |
| A549 | 28.3 |
| MCF7 | 26.1 |
| PC3 | 23.8 |
Sample was tested against the human tumor cell line A549 [Lung carcinoma cell line].
| Remarks | IC90 (µg/mL) | IC50 (µg/mL) | Sample Code |
|---|---|---|---|
| 0 % | -------- | -------- | Negative control |
| 57.8% at 100ppm | 137 | 86.1 | 2d |
| 20.6% at 100ppm | -------- | -------- | 3a |
| 32.8% at 100ppm | -------- | -------- | 3b |
| 65.1% at 100ppm | 126.3 | 77.6 | 3d |
| 22.3% at 100ppm | -------- | -------- | 4a |
| 20.7% at 100ppm | -------- | -------- | 4b |
| 28.2% at 100ppm | -------- | -------- | 5a |
| 0% at 100ppm | -------- | -------- | 5b |
| 51.7% at 100ppm | 145.4 | 92.1 | 6a |
| 1.4% at 100ppm | -------- | -------- | 6b |
| 0% at 100ppm | -------- | -------- | 7c |
| 51.6% at 100ppm | 144.2 | 92.1 | 7d |
| 35.2% at 100ppm | -------- | -------- | 8d |
| 25.2% at 100ppm | -------- | -------- | 9c |
| 45.6% at 100ppm | -------- | -------- | 9d |
| 69.6% at 100ppm | 121.4 | 72.2 | 10c |
| 54.5% at 100ppm | 142.2 | 88.4 | 10d |
| 13.9% at 100ppm | -------- | -------- | 11c |
| 40.8% at 100ppm | -------- | -------- | 11d |
| 19.8% at 100ppm | -------- | -------- | 12c |
| 42.8% at 100ppm | -------- | -------- | 12d |
| 5% at 100ppm | -------- | -------- | DMSO |
Sample was tested against the human tumor cell line HePG2 [Human hepatocellular carcinoma cell line
| Remarks | IC90 (µg/mL) | IC50 (µg/mL) | Sample Code |
|---|---|---|---|
| 0 % | -------- | -------- | Negative control |
| 70.5% at 100ppm | 120.9 | 75.8 | 2d |
| -47% at 100ppm | -------- | -------- | 3a |
| 35.3% at 100ppm | -------- | -------- | 3b |
| 78.6% at 100ppm | 109.6 | 65.1 | 3d |
| 21.3% at 100ppm | -------- | -------- | 4a |
| 2.3% at 100ppm | -------- | -------- | 4b |
| 0% at 100ppm | -------- | -------- | 5a |
| 0% at 100ppm | -------- | -------- | 5b |
| 100% at 100ppm | 57.1 | 32.8 | 6a |
| 5.7% at 100ppm | -------- | -------- | 6b |
| 0% at 100ppm | -------- | -------- | 7c |
| 84.5% at 100ppm | 103.9 | 62.6 | 7d |
| 40.6% at 100ppm | -------- | -------- | 8d |
| 4.3% at 100ppm | -------- | -------- | 9c |
| 84.2% at 100ppm | 104.8 | 66.7 | 9d |
| 0% at 100ppm | -------- | -------- | 10c |
| 94.2% at 100ppm | 79.1 | 45.6 | 10d |
| 0% at 100ppm | -------- | -------- | 11c |
| 85.4% at 100ppm | 95.2 | 53.4 | 11d |
| 22.5% at 100ppm | -------- | -------- | 12c |
| 100% at 100ppm | 59.9 | 33.3 | 12d |
| 1% at 100ppm | -------- | -------- | DMSO |
Sample was tested against the human tumor cell line MCF7 [Human Caucasian breast adenocarcinoma].
| Remarks | IC90 (µg/mL) | IC50 (µg/mL) | Sample Code |
|---|---|---|---|
| 0 % | -------- | -------- | Negative control |
| 61.9% at 100ppm | 131.7 | 81.9 | 2d |
| 8.8% at 100ppm | -------- | -------- | 3a |
| 50.2% at 100ppm | -------- | -------- | 3b |
| 61.1% at 100ppm | 131.8 | 82.9 | 3d |
| 33.7% at 100ppm | -------- | -------- | 4a |
| 58.6% at 100ppm | 132.1 | 81.9 | 4b |
| 10.7% at 100ppm | -------- | -------- | 5a |
| 20.9% at 100ppm | -------- | -------- | 5b |
| 42.9% at 100ppm | -------- | -------- | 6a |
| 4.4% at 100ppm | -------- | -------- | 6b |
| 9.8% at 100ppm | -------- | -------- | 7c |
| 60.7% at 100ppm | 132.2 | 85.0 | 7d |
| 55.4% at 100ppm | 143.1 | 90.5 | 8d |
| 0% at 100ppm | -------- | -------- | 9c |
| 56.5% at 100ppm | -------- | -------- | 9d |
| 44.7% at 100ppm | -------- | -------- | 10c |
| 44.5% at 100ppm | -------- | -------- | 10d |
| 2.9% at 100ppm | -------- | -------- | 11c |
| 52.9% at 100ppm | -------- | -------- | 11d |
| 31.2% at 100ppm | -------- | -------- | 12c |
| 57.5% at 100ppm | 137.1 | 87.4 | 12d |
| 3% at 100ppm | -------- | -------- | DMSO |
Docking analysis
Compounds 2d, 3a, 3b, 3d, 4a, 4b, 5a, 5b, 6a, 6b, 7c, 7d, 8d, 9c, 9d, 10c, 10d, 11c, 11d, 12c, 12d were used for docking study. All the calculations were performed using "Internal coordinate Mechanics" (Molsoft ICM 3.5-0a). Molecular modeling docking studies is performed and ICM score values (49-51) combined with hydrogen bonds formed with the surrounding amino acid residues help to predict the correct binding geometry for each binder at the active site. The molecular docking was performed into the hydrophobic site of EGFR with the aim to predict antitumor activity of compounds of the study (2d, 3a, 3b, 3d, 4a, 4b, 5a, 5b, 6a, 6b, 7c, 7d, 8d, 9c, 9d, 10c, 10d, 11c, 11d, 12c, 12d) against A549, HePG2 and MCF7 cell lines.
As shown in Table 5, Erlotinib (ligand) reveals ICM score of -90.54 and forms 3 H bonds with Met769, Cys773 and Gln767 (Figure 3), the target compounds elicited binding affinities (ICM scores range from -40.86 to -73.01). Compounds 10d, 12d, 8d, 11d, 9d showed activity probably due to their high ICM scores which ranged from -62.33 to -73.01 however compounds 4a, 6b, 7c, 5a are biologically inactive; they have low ICM scores of ranges from -40.86 to -50.44.
Docking of compounds on EGFR
| Length of H-bond Å | Amino acid residues forming the hydrogen bonds | Atom of ligand involved | No. of H-bonds | ICM score (∆G) | Cpd No |
|---|---|---|---|---|---|
| 1.90 | Met769 | m of M n3 | 3 | -90.54 | Erlotinib |
| 1.66 | Lys721 | m of M o1 | 1 | -50.98 | 2d |
| 2.65 | Thr766 | m of M n1 | 2 | -54.01 | 3a |
| 2.73 | Ile 758 | m of M o3 | 1 | -54.34 | 3b |
| 1.64 | Gln958 | m of M o2 | 1 | -56.61 | 3d |
| 2.62 | Lys721 | m of M n3 | 3 | -50.44 | 4a |
| 2.65 | Thr766 | m of M o2 | 2 | -58.07 | 4b |
| 2.08 | Asn784 | m of M o2 | 3 | -40.86 | 5a |
| 2.27 | Gly 786 | m of M n2 | 2 | -53.34 | 5b |
| 1.59 | Lys721 | m of M n4 | 6 | -50.45 | 6a |
| 2.72 | Asp 783 | m of M n3 | 6 | -49.58 | 6b |
| 2.32 | Gln 677 | m of M o1 | 4 | -42.33 | 7c |
| 2.39 | Lys 782 | m of M h16 | 3 | -56.93 | 7d |
| 2.78 | Thr766 | m of M o2 | 2 | -66.51 | 8d |
| 1.98 | Met769 | m of M o1 | 1 | -59.05 | 9c |
| 1.55 | Asp 783 | m of M h15 | 1 | -62.33 | 9d |
| 1.81 | Asp 783 | m of M h10 | 1 | -54.63 | 10c |
| 2.18 | Lys721 | m of M o1 | 3 | -73.01 | 10d |
| 1.53 | Gln958 | m of M o1 | 1 | -50.55 | 11c |
| 1.34 | Gly 786 | m of M o2 | 2 | -66.26 | 11d |
| 2.46 | Gln958 | m of M n5 | 1 | -56.70 | 12c |
| 2.13 | Gly786 | m of M n2 | 2 | -68.71 | 12d |
Conclusion
A novel series of some new quinazolin derivatives were synthesized and evaluated as antitumor agents against human carcinoma cell lines (HePG2– MCF7– A549). The antitumor activity results exhibited that, compounds 2d, 3d, 6a, 7d, 10c, 10d showed significant and selective inhibition for A549 (Table 2) (Figure 4). On the other hand, compounds 2d, 3d, 6a, 7d, 9d, 10d, 11d, 12d showed significant and selective inhibition for HePG2 (Table 3) (Figure 5). Compounds 2d, 3d, 4b, 7d, 8d, 12d showed significant inhibition for MCF7 (Table 4) (Figure 6) comparing to the used reference drug Doxorubicin. Docking result shows that compound 10d have high ICM score -73.01 forms 3 H bonds with Lys721 and Asp831 (Figure 7). However, compound 5a has low ICM scores -40.86 forms 3 H bonds with Asn784, Ile 785 and Gly 959 (Figure 8).
Structure-activity relationship
The activity of the tested compounds could be correlated to structure variation and modifications. By investigating the variation in the selectivity of the tested compounds over the three cell lines, it was revealed that: (1) the activity of the designed compounds is dependent upon the substituent at the R positions. The obtained screening results showed that, nearly all of the compounds containing N-phenyl aniline showed significant inhibition for the tested three cell lines (2). Cyclization of compound 2d afforded compound 3d (44) with the increase in activity against A549 with IC50 values 86.1 and 77.6 µg/mL, respectively, and for HePG2 with IC50 values 75.8 and 65.1 µg /mL, respectively, while result in a little decrease in activity against MCF7 with IC50 values 81.9 and 82.9 µg /mL, respectively (Table 2, 3, 4) (3). Compounds which have-CSNHPh group were found to be more active in the biological activities discussed in this paper than compounds which have –H. These results suggest that electron withdrawing hydrophilic substitutes (e.g.,-CSNHPh) are more desirable for achieving the desired activity. Also Certain isothiocyanates have also been shown to bind to the mutated p53 proteins found in many types of tumors, causing an increase in the rate of cell death (4). Compounds which have CO2CH2Cl yielded the least active series of compounds in this study. Which suggests that electron withdrawing groups with lipophilic characteristics like–Cl may not be an ideal substitution to get the good activity of the designed compounds.
References
-
1.
Ammar YA, Mohamed Y, El-Sharief A, El-Gaby M, Abbas S. Synthesis of some biologically active 4 (3H)-quinazolinones derived from 2, 3-pyridine dicarboxylic anhydride. Chem Sci J. 2011;2:15.
-
2.
Grover G, Kini SG. Synthesis and evaluation of new quinazolone derivatives of nalidixic acid as potential antibacterial and antifungal agents. Eur J Med Chem. 2006;41:256-262. [PubMed ID: 16260068].
-
3.
Waisser K, Gregor J, Dostál H, Kuneš J, Kubicová L, Klimešová V, Kaustová J. Influence of the replacement of the oxo function with the thioxo group on the antimycobacterial activity of 3-aryl-6, 8-dichloro-2H-1, 3-benzoxazine-2, 4 (3H)-diones and 3-aryl quinazoline-2, 4 (1H, 3H)-diones. Farmaco. 2001;56:803-807. [PubMed ID: 11718275].
-
4.
Tiwari AK, Singh VK, Bajpai A, Shukla G, Singh S, Mishra AK. Synthesis and biological properties of 4-(3H)-quinazolone derivatives. Eur J Med Chem. 2007;42:1234-1238. [PubMed ID: 17321640].
-
5.
Martin TA, Wheeler AG, Majewski RF, Corrigan JR. Sulfanilamidoquinazolines. J Med Chem. 1964;7:812-814. [PubMed ID: 14262820].
-
6.
Alagarsamy V, Pathak US. Synthesis and antihypertensive activity of novel 3-benzyl-2-substituted-3H-[1, 2, 4] triazolo [5, 1-b] quinazolin-9-ones. Bioorg Med Chem. 2007;15:3457-3462. [PubMed ID: 17391966].
-
7.
Garcia J, Somanathan R, Rivero I, Aguirre G, Hellberg L. Synthesis of deuterium-labeled antihypertensive 3-(4-phenyl-1′-piperazinyl)-propyl-2, 4-quinazolinedione. Synthetic Commun. 2000;30:2707-2711.
-
8.
Jen T, Dienel B, Dowalo F, Van Hoeven H, Bender P, Loev B. Synthesis of pyrrolo[2, 3,-b] [2, 3-b]isoquinoline imidazo[1, 2-b]isoquinoline, pyrrolo[2, 1-b] quinazoline, and 1, 3-thiazino [2, 3-b] quinazoline derivatives and related heterocycles as potential antihypertensive agents. J Med Chem. [PubMed ID: 4714994].
-
9.
Alagarsamy V, Giridhar R, Yadav M. Synthesis and pharmacological investigation of novel 1-substituted-4-(4-substituted phenyl)-4H -[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as a new class of h1-antihistamine agents. J Pharm Pharmacol. 2006;58:1249-1255. [PubMed ID: 16945184].
-
10.
Alagarsamy V, Giridhar R, Yadav MR. Synthesis and h1-antihistaminic activity of some novel 1-substituted-4-(3-methylphenyl)-1, 2, 4-triazolo [4, 3-a] quinazolin-5 (4H)-ones. Biol Pharm Bull. 2005;28:1531. [PubMed ID: 16079509].
-
11.
Alagarsamy V, Giridhar R, Yadav MR. Corrigendum to synthesis and pharmacological investigation of novel 1-substituted-4-phenyl-1, 2, 4-triazolo [4, 3-a] quinazolin-5 (4H)-ones as a new class of h1-antihistaminic agents. Bioorg Med Chem Lett. 2005;15:3316.
-
12.
Alagarsamy V, Giridhar R, Yadav MR. Synthesis and pharmacological investigation of novel 1-substituted-4-phenyl-1, 2, 4-triazolo[4, 3-a] quinazolin-5 (4H)-ones as a new class of h1-antihistaminic agents. Bioorg Med Chem Lett. 2005;15:1877-1880. [PubMed ID: 15780625].
-
13.
Alagarsamy V, Yadav MR, Giridhar R. Synthesis and pharmacological investigation of novel 1-alkyl-4-(4-substituted aryl/heteroaryl)-1, 2, 4-triazolo [4, 3- a] quinazolin-5 (4H)-ones as a new class of h1-antihistaminic agents. Arzneimittelforschung. 2006;56:834-841. [PubMed ID: 17260671].
-
14.
Dempcy RO, Skibo EB. Kinetic studies of 2-(2′-haloethyl) and 2-ethenyl substituted quinazolinone alkylating agents Acid-catalyzed dehydrohalogenation and alkylation involving a quinazolinone prototropic tautomer. Bioorg Med Chem Lett. 1993;1:39-43.
-
15.
Abdel-Rahman T. Synthesis of some new biologically active 2, 3-disubstituted quinazolin-4-ones. Boll Chim Farm. [PubMed ID: 9595834].
-
16.
El-Bayouki KA, Aly MM, Mohamed YA, Basyouni W, Abbas SY. Novel 4 (3H)-quinazolinone containing biologically active thiazole, pyrazole, 1, 3-dithiazole, pyridine, chromene, pyrazolopyrimidine and pyranochromene of expected biological activity. World J Chem. 2009;4:161-170.
-
17.
Hour M-J, Huang L-J, Kuo S-C, Xia Y, Bastow K, Nakanishi Y, Hamel E, Lee K-H. 6-alkylamino- and 2, 3-dihydro-3‘-methoxy-2-phenyl-4-quinazolinones and related compounds: Their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 2000;43:4479-4487. [PubMed ID: 11087572].
-
18.
Alagarsamy V, Revathi R, Meena S, Ramaseshu K, Rajasekaran S, De Clercq E. Anti-HIV, antibacterial and antifungal activities of some 2, 3-disubstituted quinazolin-4(3H)-ones. Indian J Pharm Sci. 2004;66:459-462.
-
19.
Hennequin LF, Boyle FT, Wardleworth JM, Marsham PR, Kimbell R, Jackman AL. Quinazoline antifolates thymidylate synthase inhibitors: Lipophilic analogues with modification to the C2-methyl substituent. J Med Chem. 1996;39:695-704. [PubMed ID: 8576912].
-
20.
Marsham PR, Hughes LR, Jackman AL, Hayter AJ, Oldfield J, Wardleworth JM, Bishop JA, O'Connor BM, Calvert AH. Quinazoline antifolate thymidylate synthase inhibitors: Heterocyclic benzoyl ring modifications. J Med Chem. 1991;34:1594-1605. [PubMed ID: 2033585].
-
21.
Giri RS, Thaker HM, Giordano T, Williams J, Rogers D, Sudersanam V, Vasu KK. Design, synthesis and characterization of novel 2-(2, 4-disubstituted-thiazole-5-yl)-3-aryl-3H-quinazoline-4-one derivatives as inhibitors of nf-κb and ap-1 mediated transcription activation and as potential anti-inflammatory agents. Eur J Med Chem. 2009;44:2184-2189. [PubMed ID: 19064304].
-
22.
El-Helby A, Wahab M. Design and synthesis of some new derivatives of 3H-quinazolin-4-one with promising anticonvulsant activity. Acta Pharm. 2003;53:127-138. [PubMed ID: 14764247].
-
23.
Jatav V, Mishra P, Kashaw S, Stables J. CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4 (3H)-ones. Eur J Med Chem. 2008;43:1945-1954. [PubMed ID: 18222569].
-
24.
Kadi AA, El-Azab AS, Alafeefy AM, Abdel-Hamide S. Synthesis and biological screening of some new substituted 2-mercapto-4(3H)quinazolinone analogues as anticonvulsant agents. Ariz J Pharm Sci. 2009;34:135-155.
-
25.
Kumar A, Sharma S, Bajaj K, Sharma S, Panwar H, Singh T, Srivastava V. Some new 2, 3, 6-trisubstituted quinazolinones as potent anti-inflammatory, analgesic and cox-II inhibitors. Bioorg Med Chem. 2003;11:5293-5299. [PubMed ID: 14604693].
-
26.
Alafeefy AM, Kadi AA, Al-Deeb OA, El-Tahir KE, Al-jaber NA. Synthesis and anti-inflammatory evaluation of some new quinazoline derivatives. Eur J Med Chem. 2010;45:4947-4952. [PubMed ID: 20817329].
-
27.
Mosaad S, Mohammed K, Ahmed M, Abdel-Hamide S. Synthesis of certain new 6-iodoquinazolines as potential antitubercular agents. J Appl Sci. 2004;4:302-307.
-
28.
Cao S-L, Feng Y-P, Jiang Y-Y, Liu S-Y, Ding G-Y, Li R-T. Synthesis and in-vitro antitumor activity of 4 (3H)-quinazolinone derivatives with dithiocarbamate side chains. Bioorg Med Chem Lett. 2005;15:1915-1917. [PubMed ID: 15780632].
-
29.
Joseph A, Pai A, Kedar T, Thomas AT, Singla R. Synthesis and anticancer activity of some novel 3-(1, 3, 4-thiadiazol-2-yl)-quinazolin-4-(3H)-ones. Orbital: Electron J Chem. 2010;2:158-167.
-
30.
Raghavendra NM, Thampi P, Gurubasavarajaswamy PM, Sriram D. Synthesis, antitubercular and anticancer activities of substituted furyl-quinazolin-3(4H)-ones. Arch Pharm. 2007;340:635-641.
-
31.
Skelton L, Ormerod M, Titley J, Kimbell R, Brunton L, Jackman A. A novel class of lipophilic quinazoline-based folic acid analogues: Cytotoxic agents with a folate-independent locus. Br J Cancer (1692). 1999;79.
-
32.
Xia Y, Yang Z-Y, Hour M-J, Kuo S-C, Xia P, Bastow KF, Nakanishi Y, Nampoothiri P, Hackl T, Hamel E. Synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg Med Chem Lett. 2001;11:1193-1196. [PubMed ID: 11354375].
-
33.
Zhang P, Terefenko EA, Fensome A, Zhang Z, Zhu Y, Cohen J, Winneker R, Wrobel J, Yardley J. Potent nonsteroidal progesterone receptor agonists: Synthesis and sar study of 6-aryl benzoxazines. Bioorg Med Chem Lett. 2002;12:787-790. [PubMed ID: 11859003].
-
34.
La DS, Belzile J, Bready JV, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn JC, Flynn SR, Graceffa RF. Novel 2, 3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. J Med Chem. 2008;51:1695-1705. [PubMed ID: 18311900].
-
35.
Madhavan GR, Chakrabarti R, Anantha Reddy K, Rajesh B, Balraju V, Bheema Rao P, Rajagopalan R, Iqbal J. Dual ppar-α and -γ activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential. Bioorg Med Chem. 2006;14:584-591. [PubMed ID: 16198573].
-
36.
Zhou D, Harrison BL, Shah U, Andree TH, Hornby GA, Scerni R, Schechter LE, Smith DL, Sullivan KM, Mewshaw RE. Studies toward the discovery of the next generation of antidepressants. Part 5: 3, 4-dihydro-2H -benzo [1, 4] oxazine derivatives with dual 5-ht1a receptor and serotonin transporter affinity. Bioorg Med Chem Lett. 2006;16:1338-1341. [PubMed ID: 16332439].
-
37.
Pritchard KM, Al-Rawi J, Bradley C. Synthesis, identification and antiplatelet evaluation of 2-morpholino substituted benzoxazines. Eur J Med Chem. 2007;42:1200-1210. [PubMed ID: 17336427].
-
38.
Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-zd1839 (iressa). Curr Opin Oncol. 2001;13:491-498. [PubMed ID: 11673690].
-
39.
Barlési F, Tchouhadjian C, Doddoli C, Villani P, Greillier L, Kleisbauer JP, Thomas P, Astoul P. Gefitinib (zd1839, iressa) in non-small-cell lung cancer: A review of clinical trials from a daily practice perspective. Fundam Clin Pharmacol. 2005;19:385-393. [PubMed ID: 15910663].
-
40.
Dhillon S, Wagstaff AJ. Lapatinib. Drugs. 2007;67:2101-2110. [PubMed ID: 17883289].
-
41.
El-Azab AS, Al-Omar MA, Abdel-Aziz AA-M, Abdel-Aziz NI, El-Sayed MA-A, Aleisa AM, Sayed-Ahmed MM, Abdel-Hamide SG. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study. Eur J Med Chem. 2010;45:4188-4198. [PubMed ID: 20599299].
-
42.
Ganjoo KN, Wakelee H. Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biol Targets Ther. 2007;1:335.
-
43.
Kopper L. Lapatinib: A sword with two edges. Pathol Oncol Res. 2008;14:1-8. [PubMed ID: 18409020].
-
44.
Walaa SE, Neama AM, Weam SE, Emad MMK, Khaled M. Synthesis, and evaluation of cytotoxic activities of novel quinazolin derivatives. Int J Res Phar Sci. 2015;6(1):62-74.
-
45.
Fathalla OAE-FM, Kassem EM, Ibrahem NM, Kamel MM. Synthesis of some new quinazolin-4-one derivatives and evaluation of their antimicrobial and anti-inflammatory effects. Acta Pol Pharm. 2008;65:11-20. [PubMed ID: 18536168].
-
46.
Mosmann T. Rapid colorimetric assays for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63. [PubMed ID: 6606682].
-
47.
El-Menshawi BS, Fayad W, Mahmoud K, El-Hallouty SM, El-Manawaty M, Olofsson MH, Linder S. Screening of natural products for therapeutic activity against solid tumors. Indian J Exp Biol. 2010;48.
-
48.
Thabrew M, Hughes RD, Mcfarlane IG. Screening of hepatoprotective plant components using a hepg2 cell cytotoxicity assay. J Pharm Pharmacol. 1997;49:1132-1135. [PubMed ID: 9401951].
-
49.
Anderson A, Weng Z. Vrdd: Applying virtual reality visualization to protein docking and design. J Mol Graph Model. 1999;17:180-186. [PubMed ID: 10736775].
-
50.
Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol. 2004;337:209-225. [PubMed ID: 15001363].
-
51.
Halperin I, Ma B, Wolfson H, Nussinov R. Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins. 2002;47:409-443. [PubMed ID: 12001221].